Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network

C. M. Sloan; L. J. Sherrard; G. G. Einarsson; L. J. Dupont; S. van Koningsbruggen-Rietschel; N. J. Simmonds; D. G. Downey

doi:10.1016/S1569-1993(23)00625-2

Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network

C. M. Sloan, L. J. Sherrard, G. G. Einarsson, L. J. Dupont, S. van Koningsbruggen-Rietschel, N. J. Simmonds, D. G. Downey

Research output: Contribution to journal › Meeting abstract › peer-review

Abstract

Original language	English
Article number	P253
Pages (from-to)	S143
Number of pages	1
Journal	Journal of Cystic Fibrosis
Volume	22
Issue number	Supplement 2
DOIs	https://doi.org/10.1016/S1569-1993(23)00625-2
Publication status	Published - 09 Jun 2023
Event	46th European Cystic Fibrosis Conference 2023 - Vienna, Austria Duration: 07 Jun 2023 → 10 Jun 2023

Access to Document

10.1016/S1569-1993(23)00625-2Licence: Unspecified

Levofloxacin: reducing the risk of Pseudomonas aeruginosa resistance
Sloan, C. M. (Author), Downey, D. (Supervisor) & Sherrard, L. (Supervisor), Dec 2024
Student thesis: Doctoral Thesis › Doctor of Philosophy

Cite this

Sloan, C. M., Sherrard, L. J., Einarsson, G. G., Dupont, L. J., van Koningsbruggen-Rietschel, S., Simmonds, N. J., & Downey, D. G. (2023). Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network. Journal of Cystic Fibrosis, 22 (Supplement 2), S143. Article P253. https://doi.org/10.1016/S1569-1993(23)00625-2

@article{cdbabba703c645ad9e3a2ccfa26b9cdd,

title = "Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network",

author = "Sloan, {C. M.} and Sherrard, {L. J.} and Einarsson, {G. G.} and Dupont, {L. J.} and {van Koningsbruggen-Rietschel}, S. and Simmonds, {N. J.} and Downey, {D. G.}",

year = "2023",

month = jun,

day = "9",

doi = "10.1016/S1569-1993(23)00625-2",

language = "English",

volume = "22 ",

pages = "S143",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "Supplement 2",

note = "46th European Cystic Fibrosis Conference 2023, ECFS 2023 ; Conference date: 07-06-2023 Through 10-06-2023",

}

Sloan, CM, Sherrard, LJ , Einarsson, GG, Dupont, LJ, van Koningsbruggen-Rietschel, S, Simmonds, NJ & Downey, DG 2023, 'Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network', Journal of Cystic Fibrosis, vol. 22 , no. Supplement 2, P253, pp. S143. https://doi.org/10.1016/S1569-1993(23)00625-2

Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network. / Sloan, C. M.; Sherrard, L. J.; Einarsson, G. G. et al.
In: Journal of Cystic Fibrosis, Vol. 22 , No. Supplement 2, P253, 09.06.2023, p. S143.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network

AU - Sloan, C. M.

AU - Sherrard, L. J.

AU - Einarsson, G. G.

AU - Dupont, L. J.

AU - van Koningsbruggen-Rietschel, S.

AU - Simmonds, N. J.

AU - Downey, D. G.

PY - 2023/6/9

Y1 - 2023/6/9

U2 - 10.1016/S1569-1993(23)00625-2

DO - 10.1016/S1569-1993(23)00625-2

M3 - Meeting abstract

SN - 1569-1993

VL - 22

SP - S143

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - Supplement 2

M1 - P253

T2 - 46th European Cystic Fibrosis Conference 2023

Y2 - 7 June 2023 through 10 June 2023

ER -

Sloan CM, Sherrard LJ , Einarsson GG, Dupont LJ, van Koningsbruggen-Rietschel S, Simmonds NJ et al. Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network. Journal of Cystic Fibrosis. 2023 Jun 9;22 (Supplement 2):S143. P253. doi: 10.1016/S1569-1993(23)00625-2

Optimisation of inhaled antibiotic prescribing for Pseudomonas aeruginosa infections in people with cystic fibrosis: further insights from principal investigators of the ECFS Clinical Trials Network

Abstract

Access to Document

Fingerprint

Student theses

Levofloxacin: reducing the risk of Pseudomonas aeruginosa resistance

Cite this